| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1185: Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | acalabrutinib (Calquence) |
| Formulation | 100 mg film-coated tablets |
| Reference number | 5387 |
| Indication | In combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia |
| Company | AstraZeneca UK Limited |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/07/2026 |
| NICE guidance | |